Comparative Pharmacology
Head-to-head clinical analysis: DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE versus MINIPRESS XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE versus MINIPRESS XL.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE vs MINIPRESS XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and reduces peripheral vascular resistance via blockade of postsynaptic alpha-1 receptors on vascular smooth muscle.
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
Initial: 1 mg orally once daily at bedtime, gradually increased to 2-20 mg/day in divided doses.
None Documented
None Documented
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
2–3 hours in normotensive patients; prolonged to 6–10 hours in hypertension; extended by renal impairment (up to 4–6 hours in creatinine clearance <10 mL/min)
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
Renal (primarily as metabolites, ~90% in urine, <10% unchanged), biliary/fecal (~10%)
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker